MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies.

Autor: Radia, Deepti, DeAngelo, Daniel, Deininger, Michael W., Reiter, Andreas, Sen, Jayita, Lin, Hui Min, Dimitrijevic, Sasa, Gotlib, Jason
Zdroj: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS367-S368, 2p
Databáze: Complementary Index
Externí odkaz: